friends of FSH Research

Tagline

Bruce M Wentworth PhD

VP Discovery Research


Sarapta Therapeutics

Dr. Wentworth, PhD has been Vice President of Discovery Research at Sarepta Therapeutics, Inc. since March 2015. He joined Sarepta in March 2015. He served as Science Director at MG Biotherapeutics LLC. In 1991, he joined Biosurface Technology, Inc. Dr. Wentworth’s career includes extensive R&D experience in the cell therapy and rare disease area. In his more than 20 years of industry experience at Genzyme and later Sanofi, he led discovery and translational research on burn wound and cardiac repair programs as well as multiple rare disease programs especially pertaining to muscle genetic diseases. He has been the co-leader of a team of scientists investigating cell and gene-based therapy techniques for repairing infarcted hearts and treating ischemic diseases. He served as a Senior Director for Rare Disease Research. Dr. Wentworth was a Fellow of the American Heart Association studied the mechanisms of muscle-specific gene expression at Harvard and Boston University Medical Schools. Dr. Wentworth attended Boston University with BA in 1976 and MA in 1980 and the University of Massachusetts Medical School Graduate Program in Worcester, Massachusetts with PhD in 1987 where he sequenced and studied expression of the mouse preproinsulin genes.

Chairman, The Science Offsite Conference, 2014
Genzyme-Sanofi Hub R&D annual conference.

Co-Leader of the 2013 Genzyme Science Offsite conference.

Group Leader, Muscle Research. Investigating various therapeutic interventions for muscle genetic diseases.

Co-founder and research leader for Medtronic-Genzyme Biotechnology, a joint venture investigating uses of cell therapy for cardiovascular disease.

Science Portfolio Leader, Cardiovascular Disease. Investigated various cell, gene, and protein therapeutic approaches for cardiovascular disease.

Keratinocyte Research Group Leader. Investigated novel concepts for keratinocyte grafting for severe burns as well as process improvements for autograft delivery.

Specialties:
Antisense oligonucleotides and their uses in vivo
Therapeutic development for skeletal muscle diseases
Cell based therapies for cardiovascular disease
Skin and cartilage repair-regeneration
Paella Valencian